Neonatal myasthenia gravis (Q88652): Difference between revisions

← Older edit

@@ Property / CURIE @@
+CID11:ID_1274860004
@@ Property / CURIE: CID11:ID_1274860004 / rank @@
+Normal rank
@@ Property / Canary Token @@
+dki-india-ID_1274860004
@@ Property / Canary Token: dki-india-ID_1274860004 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank

Latest revision as of 14:59, 15 August 2026

Neonatal Myasthenia Gravis (MG) refers to the clinical MG syndrome caused by passively transferred maternal auto-antibodies to the newborn. This disease mechanism has been described for all three major forms of MG, including Acetylcholine receptor, Muscle-specific kinase and Lambert-Eaton myasthenic syndrome antibodies. Frequency is 10-30%. The neonates present with weakness, hypotonia, respiratory depression. The symptoms subside over 1 to 4 weeks.

Language	Label	Description	Also known as
default for all languages	ID_1274860004
English	Neonatal myasthenia gravis	Neonatal Myasthenia Gravis (MG) refers to the clinical MG syndrome caused by passively transferred maternal auto-antibodies to the newborn. This disease mechanism has been described for all three major forms of MG, including Acetylcholine receptor, Muscle-specific kinase and Lambert-Eaton myasthenic syndrome antibodies. Frequency is 10-30%. The neonates present with weakness, hypotonia, respiratory depression. The symptoms subside over 1 to 4 weeks.